U.S. Court Permits Generic Version of Teva MS Drug a Year Sooner

Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015.

Send in e-mailSend in e-mail

Comments